• Profile

Biomarkers evolution in metastatic colorectal cancer (mCRC): Dr. PK Julka

M3 India Newsdesk Jan 21, 2021

Dr. Pramod Kumar Julka elaborates on the advancements made in the identification of predictive and prognostic biomarkers for personalising colorectal cancer treatments. The video also summarises the newer somatic mutations and their clinical utility.

Watch Dr. Pramod Kumar Julka speak about-

  • Molecular CRC classification- CIN, CIMP, and MSI pathway
  • Detection of molecular biomarkers
  • RAS & BRAF family of signaling proteins
  • Pathways to repair deficiency in CRC
  • HER family of proteins
  • Somatic biomarkers and clinical implications plus supporting guidelines available for CRC

Disclaimer- The views and opinions expressed in this article are those of the author's and do not necessarily reflect the official policy or position of M3 India.

The speaker, Dr. Pramod Kumar Julka is the Senior Director at Max Oncology Day Care Centre, Delhi.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen